Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GHRS

GH Research PLC

May 03 • 04:00PM ET

11.68

Dollar change +0.49
Percentage change 4.38	%

Healthcare • Biotechnology • Ireland • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: EIRL ONEQ PSIL GWX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	43.70%	Shs Outstand	52.03M	Perf Week	11.13%
Market Cap	607.71M	Forward P/E	-	EPS next Y	-1.22	Insider Trans	0.00%	Shs Float	29.29M	Perf Month	5.99%
Income	-32.32M	PEG	-	EPS next Q	-0.22	Inst Own	56.12%	Short Float	4.94%	Perf Quarter	52.68%
Sales	0.00M	P/S	-	EPS this Y	-27.45%	Inst Trans	-2.83%	Short Ratio	11.73	Perf Half Y	65.44%
Book/sh	4.03	P/B	2.90	EPS next Y	-40.31%	ROA	-13.84%	Short Interest	1.45M	Perf Year	37.41%
Cash/sh	3.03	P/C	3.85	EPS next 5Y	-	ROE	-14.31%	52W Range	5.05 - 14.64	Perf YTD	101.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-253.12%	ROI	-15.37%	52W High	-20.22%	Beta	0.80
Dividend TTM	-	Quick Ratio	22.06	Sales past 5Y	0.00%	Gross Margin	-	52W Low	131.29%	ATR (14)	0.74
Dividend Ex-Date	-	Current Ratio	22.06	EPS Y/Y TTM	-17.37%	Oper. Margin	0.00%	RSI (14)	58.15	Volatility	7.78% 5.97%
Employees	49	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.40
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	28.64%	Payout	-	Rel Volume	1.08	Prev Close	11.19
Sales Surprise	-	EPS Surprise	31.82%	Sales Q/Q	-	Earnings	May 03 BMO	Avg Volume	123.29K	Price	11.68
SMA20	5.03%	SMA50	14.23%	SMA200	31.00%	Trades		Volume	132,794	Change	4.38%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-22	Initiated	H.C. Wainwright	Buy	$45
Jun-16-22	Initiated	ROTH Capital	Buy	$66

May-03-24 01:53PM	GHRS Stock Earnings: GH Research Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 09:55AM	How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28% (Zacks)
Feb-29-24 07:00AM	GH Research Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire) +7.90%
Jan-18-24 04:30PM	GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression (GlobeNewswire)
09:55AM	Loading…
Jan-16-24 09:55AM	Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -7.32%
Dec-19-23 11:07AM	15 Best Falling Stocks To Buy Now (Insider Monkey) +9.13%
Nov-09-23 04:45PM	GH Research Reports Third Quarter Financial Results and Provides Business Updates (GlobeNewswire)
Sep-29-23 04:45PM	GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression (GlobeNewswire)
Aug-23-23 07:00AM	GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-17-23 11:53AM	Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation (Simply Wall St.)
Jul-06-23 09:40AM	Its Really a Brain Chemistry Issue: Elon Musk Embraces Ketamine in the Battle Against Depression Here Are 2 Psychedelic Stocks That Analysts Like (TipRanks)
Jun-29-23 08:00AM	The 3 Best Psychedelic Stocks to Buy Now (InvestorPlace)
07:30AM	Loading…
May-11-23 07:30AM	GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks) +14.78%
Mar-12-23 12:22PM	10 Best Psychedelic Stocks to Buy According to Hedge Funds (Insider Monkey)
Mar-02-23 07:00AM	GH Research Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-07-23 10:15AM	GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-09-23 07:30AM	GH Research Provides Business Updates and Highlights Key Upcoming Milestones (GlobeNewswire) -13.00%
Nov-21-22 12:22PM	7 Short-Squeeze Stocks for Bold Contrarians to Consider (InvestorPlace) -6.67%
Nov-10-22 07:05AM	GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +7.03%
Sep-14-22 09:55AM	Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High? (Zacks) +9.26%
Aug-30-22 03:02PM	7 Psychedelics Stocks to Buy for a Big Drug Boom (InvestorPlace) -6.01%
Aug-29-22 09:55AM	Wall Street Analysts Predict a 206% Upside in GH Research PLC (GHRS): Here's What You Should Know (Zacks) +7.95%
Aug-23-22 07:00AM	GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +5.33%
May-18-22 07:00AM	GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -9.98%
Mar-28-22 07:04AM	GH Research Reports Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-24-22 11:48AM	We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate (Simply Wall St.)
07:10AM	Loading…
Dec-06-21 07:10AM	GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire) +21.86%
07:00AM	GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression (GlobeNewswire)
Oct-27-21 04:50AM	10 Pharma Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey) +10.61%
Sep-25-21 10:07AM	We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-23-21 05:25PM	GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-02-21 04:20PM	Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies (Benzinga) -5.64%
Jun-25-21 01:23PM	7 Companies Go Public Today. What Investors Need to Know. (Barrons.com)

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schonharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GHRS

GH Research PLC

Upgrade your FINVIZ experience